Detection of EGFR mutations in pleural effusion of patients with non-small cell lung cancer
10.3969/j.issn.1006-5725.2017.23.033
- VernacularTitle:非小细胞肺腺癌患者恶性胸水EGFR基因突变的分析
- Author:
Xiuqin YAO
1
;
Yunjian XU
;
Yumei FU
;
Zhongmin LIU
Author Information
1. 510170,广州医科大学附属第三医院荔湾医院检验科
- Keywords:
EGFR;
mutation;
pleural effusion;
circulating tumor DNA
- From:
The Journal of Practical Medicine
2017;33(23):3980-3983
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the consistency of EGFR mutations in pleural effusion in terminal non-small cell lung cancer(NSCLC)patients by amplification refractory mutation system- polymeric chain reaction (ARMS-PCR).Methods Pleural effusion from 44 cases with advanced NSCLC were collected.DNA was extract-ed from a part of pleural effusion,and EGFR gene18,19,20,and 2 l exons mutations were detected by ARMS-PCR amplification. The left part of pleural effusion was used for the pathological microscopic examination of the embedding and to evaluate the feasibility of pleural effusion direct detection.Part of the case results were compared with tissue or pleural effusion at the same time. Results The mutation rate of EGFR detection in pleural effusion was 54.5%,including 19-del(50.0%)and 21-L858R(50.0%);75.0% of pleural effusion sediment was morpho-logically diagnosed with adenocarcinoma and EGFR mutation rate was 27.3% in pleural effusion with no tumor cell. The consistent rate was 72.7% in 22 cases of pleural effusion and tissue and that was 50.0% in 16 cases of pleural effusion and plasma.The comparison between pleural effusion and organizations and plasma test results was statisti-cally significant(P < 0.05).(P < 0.05).Conclusions EGFR gene mutation rate in pleural effusion is lower than that in tumor tissue specimens in terminal NSCLC patients and tumor tissue is still the best test specimens.
